A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know – Image for illustrative purposes only (Image credits: Unsplash)
For millions of older Americans grappling with obesity, the high cost of effective weight loss medications has long posed a barrier. Medicare has historically excluded coverage for such treatments, leaving many to pay hundreds of dollars monthly out of pocket. That changes soon with a pilot initiative offering discounted access to popular GLP-1 drugs like Wegovy and Zepbound. Set to launch in just weeks, the program promises relief at a flat $50 copay, though it carries specific rules and a limited timeline.
The Medicare GLP-1 Bridge: A Temporary Coverage Shift
The Centers for Medicare & Medicaid Services announced the Medicare GLP-1 Bridge program as a short-term pilot to address affordability gaps. It will operate from July 1, 2026, through December 31, 2027, providing a pathway to weight loss drugs before any potential permanent expansion. This marks a departure from longstanding Medicare policy that prohibited payments for weight loss therapies. The initiative targets GLP-1 medications specifically approved for obesity management, including injectable and pill forms of Wegovy, the KwikPen version of Zepbound, and the Foundayo pill.
Administrators designed the program to gather data on usage and outcomes among Medicare beneficiaries. About 40% of American adults qualify as clinically obese with a BMI of 30 or higher, per Centers for Disease Control and Prevention figures, and a significant portion of those are seniors. Polling from KFF revealed that half of GLP-1 users found the drugs hard to afford, with a quarter calling it very difficult. This pilot aims to test real-world demand while controlling costs through a structured process.
Eligibility Rules Center on BMI and Health Conditions
Participation requires enrollment in a Medicare Part D prescription drug plan, but approval hinges on clinical criteria. Beneficiaries qualify with a BMI of 27 or higher if they also have conditions like heart disease or prediabetes. Those with a BMI of 35 or above gain automatic eligibility, regardless of comorbidities. Doctors must submit prior authorization requests to a central system managed by CMS contractor Humana.
Providers do not need Medicare enrollment to prescribe or request approval under this program. Once cleared, patients pick up their medication at any pharmacy for the fixed $50 copay. Current cash prices for these drugs, even with discounts via sites like TrumpRx, range from $149 to $699 monthly, depending on dosage and formulation. The program’s structure ensures predictability, as the copay remains steady even at higher doses needed for sustained results.
How It Differs from Standard Part D Coverage
Unlike routine prescriptions, the Bridge program bypasses traditional Part D plans for processing. Patients pay the $50 directly at the pharmacy after approval, simplifying access but introducing caveats. This copay does not apply toward the Part D deductible or the $2,100 annual out-of-pocket maximum. Low-income subsidy recipients, known as Extra Help participants, cannot combine it with their benefits, potentially making the fee burdensome for those on fixed incomes like modest Social Security payments.
For users already on GLP-1s for diabetes, cardiovascular risk, or sleep apnea, coverage stays through regular Part D, possibly at higher costs. Those on weight loss doses can switch if they met initial criteria, with prescribers attesting to past BMI levels. Studies indicate many regain weight after stopping these medications, underscoring the need for long-term strategies. “Fifty dollars a month sounds like a great deal compared to paying the discounted prices… but it’s a lot of money for somebody who’s living on a $750-a-month Social Security check,” noted Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF.
Costs, Challenges, and the Path Forward
The program’s affordability stands out against list prices: Wegovy injectables from $199 to $399, Zepbound KwikPen up to $699, Wegovy pills to $299, and Foundayo to $349 on discount platforms. Yet trade-offs persist, including the 18-month limit extended from an initial six months after insurers balked at a follow-on voluntary plan. A KFF analysis once pegged nearly 14 million overweight or obese Medicare beneficiaries, hinting at substantial uptake potential. CMS has not released cost projections, but experts anticipate billions in added Medicare spending annually.
Extending the pilot gives time for data collection and negotiations with private insurers. The Trump administration’s original two-phase proposal sought to transition costs to plans, but low participation prompted the change. Beneficiaries must weigh the temporary nature against immediate savings. For those eyeing GLP-1s, consulting a doctor soon could position them for July access. As obesity affects health outcomes in aging populations, this bridge offers a glimpse of evolving coverage, though its legacy depends on what follows in 2028.
